FDA forms Task Force Dengvaxia

A TASK force to specifically address issues relating to Dengue Tetravalent Vaccine, Inc., which is registered as Dengvaxia, was created by the Food and Drug Administration (FDA).

The special task force is mandated to “conduct comprehensive review of all the records relating to the approval of the said vaccine, submit appropriate recommendations, and take appropriate actions, having in mind its fundamental mandate to protect and promote the health of the people.”

This was after the Sanofi Pasteur, Inc. (SPI) has recently released clinical findings stating the possible effects of the vaccine.

The task force will also be in charge of the retrieval of all files concerning the vaccine, issuance of recommendations, and the taking appropriate actions together with other agencies. Because of this, FDA stated that any documents relating to Dengvaxia that are forwarded to any agencies aside from the special task force will not be considered official.

“The public is thus advised that all applications, requests, letters, correspondence and other documents related to Dengvaxia should be directly forwarded to the FDA Action Center (FDAC), Attention: Atty. Kevin Jardine S. Lozano, TF Dengvaxia Secretary.

In Davao City, latest reports revealed that private institutions that administered Dengvaxia vaccine to Dabawenyo children committed to monitor the clients. According to Department of Health (DOH) Davao report, there are three Dabawenyo children vaccinated with Dengvaxia vaccine. JPA